This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Alovudine F-18
DrugBank Accession Number
DB14930
Background

Alovudine F-18 is under investigation in clinical trial NCT02819024 (Dexamethasone Effects in Patients With Refractory Non-Small Cell Lung Cancer Using FLT Positron Emission Tomography).

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 243.225
Monoisotopic: 243.088469574
Chemical Formula
C10H13FN2O4
Synonyms
  • 18F-FLT
  • FLUOROTHYMIDINE F-18

Pharmacology

Indication

Not Available

Pharmacology
Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Contraindications
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Adverseeffects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Adenovirus type 7 vaccine liveThe therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Alovudine F-18.
Anthrax vaccineThe therapeutic efficacy of Anthrax vaccine can be decreased when used in combination with Alovudine F-18.
Bacillus calmette-guerin substrain connaught live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain connaught live antigen can be decreased when used in combination with Alovudine F-18.
Bacillus calmette-guerin substrain russian BCG-I live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain russian BCG-I live antigen can be decreased when used in combination with Alovudine F-18.
Bacillus calmette-guerin substrain tice live antigenThe therapeutic efficacy of Bacillus calmette-guerin substrain tice live antigen can be decreased when used in combination with Alovudine F-18.
BCG vaccineThe therapeutic efficacy of BCG vaccine can be decreased when used in combination with Alovudine F-18.
Human adenovirus e serotype 4 strain cl-68578 antigenThe therapeutic efficacy of Human adenovirus e serotype 4 strain cl-68578 antigen can be decreased when used in combination with Alovudine F-18.
Rubella virus vaccineThe therapeutic efficacy of Rubella virus vaccine can be decreased when used in combination with Alovudine F-18.
Typhoid Vaccine LiveThe therapeutic efficacy of Typhoid Vaccine Live can be decreased when used in combination with Alovudine F-18.
Varicella zoster vaccine (live/attenuated)The therapeutic efficacy of Varicella zoster vaccine (live/attenuated) can be decreased when used in combination with Alovudine F-18.
Interactions
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
2X1K91UT6N
CAS number
287114-80-1
InChI Key
UXCAQJAQSWSNPQ-ZIVQXEJRSA-N
InChI
InChI=1S/C10H13FN2O4/c1-5-3-13(10(16)12-9(5)15)8-2-6(11)7(4-14)17-8/h3,6-8,14H,2,4H2,1H3,(H,12,15,16)/t6-,7+,8+/m0/s1/i11-1
IUPAC Name
1-[(2R,4S,5R)-4-(¹⁸F)fluoro-5-(hydroxymethyl)oxolan-2-yl]-5-methyl-1,2,3,4-tetrahydropyrimidine-2,4-dione
SMILES
CC1=CN([C@H]2C[C@H]([18F])[C@@H](CO)O2)C(=O)NC1=O

References

General References
Not Available
ChemSpider
8053786
ZINC
ZINC000100658715

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
2CompletedDiagnosticBreast Cancer Stage IIIc / Breast Cancer, Stage IIIB / Stage IIB Breast Cancer / Stage IIIA Breast Cancer1
2CompletedTreatmentAdvanced Non Small Cell Lung Cancer (NSCLC) / Recurrent Non-Small Cell Lung Carcinoma / Stage IB Non-Small Cell Lung Carcinoma / Stage IIA Non-Small Cell Lung Carcinoma / Stage IIB Non-Small Cell Lung Carcinoma / Stage IIIA Non Small Cell Lung Cancer1
2CompletedTreatmentBreast Cancer / Tumors Metastatic to Brain1
1RecruitingDiagnosticGliomas1
1TerminatedDiagnosticTumors of the Central Nervous System1
1, 2TerminatedDiagnosticCancer Brain / Malignancies / Malignant Lymphomas / Tumors, Solid1
0Active Not RecruitingDiagnosticGraft Versus Host Disease (cGvHD)1
0CompletedDiagnosticAdult Supratentorial Primitive Neuroectodermal Tumor (PNET) / Ewing Sarcoma of Bone / Extraosseous Ewing's Sarcoma (EOE) / Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor / Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor1
0RecruitingDiagnosticAcute Lymphoblastic Leukemia (ALL) / Acute Myeloid Leukemia (AML)1
0WithdrawnDiagnosticSoft Tissue Sarcoma, Adult, Stage II / Soft Tissue Sarcoma, Adult, Stage IIB / Soft Tissue Sarcoma, Adult, Stage IIC / Stage IIA Adult Soft Tissue Sarcoma / Stage III Adult Soft Tissue Sarcoma / Stage IV Adult Soft Tissue Sarcoma1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility79.2 mg/mLALOGPS
logP-0.6ALOGPS
logP-0.23ChemAxon
logS-0.49ALOGPS
pKa (Strongest Acidic)10.11ChemAxon
pKa (Strongest Basic)-3ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area78.87 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity53.72 m3·mol-1ChemAxon
Polarizability22.22 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at May 20, 2019 14:35 / Updated at June 12, 2020 16:53